Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Open accessThe DOI matches its Crossref record; 339 of the 341 references it cites were found in a registry or an index.
Abstract
Background: Pharmacological augmentation is a recommended strategy for patients with treatment-resistant depression. A range of guidelines provide advice on treatment selection, prescription, monitoring and discontinuation, but variation in the content and quality of guidelines may limit the provision of objective, evidence-based care. This is of importance given the side effect burden and poorer long-term outcomes associated with polypharmacy and treatment-resistant depression. This review provides a definitive overview of pharmacological augmentation recommendations by assessing the quality of guidelines for depression and comparing the recommendations made. Methods: A systematic literature search identified current treatment guidelines for depression published in English. Guidelines were quality assessed using the Appraisal of Guidelines for Research and Evaluation II tool. Data relating to the prescription of pharmacological augmenters were extracted from those developed with sufficient rigor, and the included recommendations compared. Results: Total of 1696 records were identified, 19 guidelines were assessed for quality, and 10 were included. Guidelines differed in their quality, the stage at which augmentation was recommended, the agents included, and the evidence base cited. Lithium and atypical antipsychotics were recommended by all 10, though the specific advice was not consistent. Of the 15 augmenters identified, no others were universally recommended. Conclusions: This review provides a comprehensive overview of current pharmacological augmentation recommendations for major depression and will support clinicians in selecting appropriate treatment guidance. Although some variation can be accounted for by date of guideline publication, and limited evidence from clinical trials, there is a clear need for greater consistency across guidelines to ensure patients receive consistent evidence-based care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
Clinical Practice Guidelines We Can Trust
Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Board on Health Care Services, & Institute of Medicine (2011) · National Academies Press eBooks · doi:10.17226/13058 · Cited by 3,081
Research works printed but not linked: 12
- Agid, 2006, The “delayed onset” of antipsychotic action–an idea whose time has come and gone, J Psychiatry Neurosci, 31, 93
- DeBattista, 2003, Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study, J Clin Psychiatry, 64, 1057, 10.4088/JCP.v64n0911 · DOI · Paper page
- FDA, 2019, February 12, 2019: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee - 02/12/2019 - 02/12/2019
- Fond, 2014, Ketamine administration in depressive disorders: a systematic review and meta-analysis, Psychopharmacology (Berl), 231, 3663, 10.1007/s00213-014-3664-5 · DOI · Paper page
- Hurley, 2002, Lamotrigine update and its use in mood disorders, Ann Pharmacother, 36, 860, 10.1345/aph.1A102 · doi:10.1345/aph.1a102 · Paper page
- Jensen, 1992, Combining nortriptyline and lithium in elderly depressed patients: a double-blind, placebo-controlled study, Lithium, 3, 259
- National Institute for Health and Clinical Excellence (NICE), 2009, The treatment and management of depression in adults (Updated Edition)
- Schindler, 2007, Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study, Int Clin Psychopharmacol, 22, 179, 10.1097/YIC.0b013e328014823d · DOI · Paper page
- Serafini, 2014, The role of ketamine in treatment-resistant depression: a systematic review, Curr Neuropharmacol, 12, 444, 10.2174/1570159X12666140619204251 · DOI · Paper page
- Suehs, 2008, Texas medication algorithm project procedural manual: major depressive disorder algorithms. Austin, TX: The Texas Department of State Health Services
- Taylor, 2015, The Maudsley prescribing guidelines in psychiatry
- Trivedi, 2006, Medication augmentation after the failure of SSRIs for depression, N Engl J Med, 354, 1243, 10.1056/NEJMoa052964 · DOI · Paper page
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationSforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
“Moreover, guidelines on how to treat TRD/PRD, such as pharmacological augmentation, are not consistent [14], and evidence on effectiveness is sparse [15].”
BackgroundSelf-citationMalhi, G. S., Bell, E., Singh, A., Bassett, D. L., Berk, M., Boyce, P. M., Bryant, R. A., Gitlin, M. J., Hamilton, A., Hazell, P., et al. (2020) · Bipolar Disorders · doi:10.1111/bdi.13035 · Cited by 131
Self-citationScott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221104058 · Cited by 87
“The exception to this rule was buspirone, for which the ES and 95% CIs were considerably higher when TRD was defined as 2 FTs (1 FT = ES = 0.84, 95% CI: 0.61–1.07; 2 FTs = ES = 1.57, 95% CI: 1.14–2.02), although this consisted of only one small study.”
BackgroundResultInfluentialSelf-citationLevkovich, I., & Elyoseph, Z. (2023) · Family Medicine and Community Health · doi:10.1136/fmch-2023-002391 · Cited by 83
“Scrutiny and handling of gender or socioeconomic biases.”
BackgroundVitamin B12 Supplementation: Preventing Onset and Improving Prognosis of Depression
Sangle, P., Sandhu, O., Aftab, Z., Anthony, A. T., & Khan, S. (2020) · Cureus · doi:10.7759/cureus.11169 · Cited by 100
Quan, Z., Li, H., Quan, Z., & Qing, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087098 · Cited by 39
A retrospective examination of care pathways in individuals with treatment-resistant depression
Day, E., Shah, R., Taylor, R., Marwood, L., Nortey, K., Harvey, J., McAllister-Williams, H., Geddes, J. R., Alvaro Barrera, P., Young, A. H., et al. (2021) · BJPsych Open · doi:10.1192/bjo.2021.59 · Cited by 28
Self-citationVos, C. F., Aarnoutse, R. E., de Coul, M. J. M. O., Spijker, J., Groothedde-Kuyvenhoven, M. M., Mihăescu, R., Wessels‐Basten, S. J. W., Rovers, J. J. E., ter Hark, S. E., Schene, A. H., et al. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03490-x · Cited by 31
Overview of treatment-resistant depression
Li, C. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.03.007 · Cited by 41
When and How to Use Lithium Augmentation for Treating Major Depressive Disorder
Ercis, M., Özerdem, A., & Singh, B. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23ac14813 · Cited by 24
Costa, T., Menzat, B., Engelthaler, T., Fell, B., Franarin, T., Roque, G., Wei, Y., Zhang, X., & McAllister-Williams, R. H. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221090628 · Cited by 22
“Olanzapine was the next most common augmentation agent, despite only being a second-line recommendation in most guidelines (Cleare et al., 2015; Taylor et al., 2020).”
BackgroundFurukawa, Y., Hamza, T., Cipriani, A., Furukawa, T. A., Salanti, G., & Ostinelli, E. G. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.165 · Cited by 25
Yrondi, A., Javelot, H., Nobile, B., Boudieu, L., Aouizerate, B., Llorca, P., Charpeaud, T., Bennabi, D., Lefrere, A., & Samalin, L. (2024) · L Encéphale · doi:10.1016/j.encep.2023.11.029 · Cited by 26
Lähteenvuo, M., Taipale, H., Tanskanen, A., Rannanpää, S., & Tiihonen, J. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.010 · Cited by 20
Cleare, A. J., Kerr-Gaffney, J., Goldsmith, K., Zenasni, Z., Yaziji, N., Jin, H., Colasanti, A., Geddes, J. R., Kessler, D., McAllister-Williams, R. H., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00028-8 · Cited by 18
Self-citationConway, C. R., Aaronson, S. T., Sackeïm, H. A., Duffy, W. J., Stedman, M., Quevedo, J., Allen, R. M., Riva‐Posse, P., Berger, M. A., Alva, G., et al. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.03.016 · Cited by 19
Furukawa, Y., Oguro, S., Obata, S., Hamza, T., Ostinelli, E. G., & Kasai, K. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13438 · Cited by 14
“Atypical antipsychotics are commonly recommended as augmentation by many guidelines.(20) Brexpiprazole is a partial agonist of dopamine D2 receptors and serotonin 5HT-1A receptors, and an antagonist of serotonin 5HT-2A receptors.”
BackgroundNoda, Y., Wada, M., Mimura, Y., Taniguchi, K., Tarumi, R., Moriyama, S., Arai, N., Tsugawa, S., Thorpe, K. E., Daskalakis, Z. J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.15881 · Cited by 21
Joseph, B., Núñez, N. A., Kung, S., Voort, J. L. V., Pazdernik, V., Schak, K. M., Boehm, S. M., Carpenter, B., Johnson, E. K., Malyshev, G., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16081164 · Cited by 18
“Current guidelines suggest lamotrigine as a well-tolerated second-line augmentation agent for TRD [34].”
BackgroundKey considerations in the pharmacological management of treatment-resistant depression
Yavi, M., Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1951225 · Cited by 15
“Although a comprehensive discussion on the nature of these interactions and a review of treatment strategies for comorbidities is beyond the scope of this discussion, we refer the interested reader to several recent guidelines on this topic [8,19].”
BackgroundSforzini, L. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100331 · Cited by 15
“Even when considering the treatment of TRD, such as pharmacological augmentation, recommendations are not consistent across current guidelines (Taylor et al., 2021) and evidence of effectiveness is sparse (Strawbridge et al., 2019a).”
Clinical and Biological Factors Are Associated with Treatment-Resistant Depression
Buoli, M., Capuzzi, E., Caldiroli, A., Ceresa, A., Esposito, C. M., Posio, C., Auxilia, A. M., Capellazzi, M., Tagliabue, I., Surace, T., et al. (2022) · Behavioral Sciences · doi:10.3390/bs12020034 · Cited by 21
“, antidepressants plus atypical antipsychotics or lithium) associated with an increased risk of side effects and less adherence to medical prescription, resulting in a further worsening of symptoms [48].”
BackgroundMa, X., Shin, J.-W., Cho, J., Han, S.-W., & Kim, D. (2023) · Letters in Applied Microbiology · doi:10.1093/lambio/ovad144 · Cited by 20
McKeown, L., Taylor, R. W., Day, E., Shah, R., Marwood, L., Tee, H., Kerr-Gaffney, J., Oprea, E., Geddes, J. R., McAllister-Williams, R. H., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221089042 · Cited by 12
“guidelines (Taylor et al., 2020), but the existing evidence does not favour one over the other, leading to clinical equipoise (Bauer et al.”
BackgroundSelf-citationOtter, M., Kothgassner, O. D., Lepuschütz, L., Drahos, S., & Plener, P. L. (2024) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-023-00684-x · Cited by 16
“Atypical antipsychotics have been mentioned as part of an augmentation regime in the treatment of resistant depression [14, 37], but are only suggested for the treat-ment of psychotic depression in minors [25].”
BackgroundLamotrigine and lithium in primary care psychiatric consultation: adoption and adverse effects
Phelps, J. R., Pipitone, O., Squires, K., & Bale, J. D. (2020) · Family Practice · doi:10.1093/fampra/cmaa131 · Cited by 12
Orsini, L. S., O’Connor, S. J., Mohwinckel, M., Marwood, L., Pahwa, A., Bryder, M. N., Dong, X., & Levine, S. P. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2113692 · Cited by 12
Self-citationStrawbridge, R., Izurieta, E., Day, E., Tee, H., Young, K., Tong, C. C. H. Y., Young, A. H., & Cleare, A. J. (2022) · Neuroscience Applied · doi:10.1016/j.nsa.2022.101014 · Cited by 12
“Bupropion is not universally considered 1st line, but is listed as such in the most recent guidelines (Taylor et al., 2020) alongside strong meta-analytic evidence lacking for other recommended TRD interventions including the SGAs olanzapine and risperidone, anticonvulsant mood stabilisers, thyroid…”
Self-citationStäuble, C. K., Lampert, M. L., Mikoteit, T., Hatzinger, M., Hersberger, K. E., & zu Schwabedissen, H. E. M. (2021) · Life · doi:10.3390/life11070673 · Cited by 12
“Notably, pharmacologic augmentation is a common strategy in the treatment of therapy-resistant MDD [28].”
BackgroundMartins-Correia, J., Fernandes, L. A., Kenny, R. P. W., Salas, B., Karmani, S. J., Inskip, A., Pearson, F., & Watson, S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.06.099 · Cited by 11
Early augmentation by using neuromodulation in psychiatric disorder: a kaleidoscopic view
Kar, S. K., & Menon, V. (2021) · CNS Spectrums · doi:10.1017/s1092852921000237 · Cited by 9
Kriner, P., Severus, E., Korbmacher, J. M., Mußmann, L., & Seemüller, F. (2023) · International Journal of Bipolar Disorders · doi:10.1186/s40345-023-00323-6 · Cited by 9
“German 2022 S3 guidelines on UD and several international guidelines, recommend Li as first-line therapy in treatment-resistant depression (Bun-desärztekammer (BÄK) et al. 2022; Taylor et al. 2020).”
BackgroundPeripartum lithium management: Early maternal and neonatal outcomes
Imaz, M. L., Torra, M., Langohr, K., Arca, G., Soy, D., Hernández, A. S., García-Esteve, L., Vieta, E., & Martín‐Santos, R. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.140 · Cited by 9
Potential Benefits of Remote Continuous Care for Depression
Forman‐Hoffman, V. L., Kvedar, J. C., & Ranta, K. (2021) · International Journal of Digital Health · doi:10.29337/ijdh.39 · Cited by 7
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
“Initial use of two or more medications is common in these medical disorders, but most guidelines for management of MDD – including moderate to severe episodes – recommend starting treatment with at least two adequately-dosed six-week monotherapy trials and introducing antidepressant medication combinations only after…”
Backgroundvon Knorring, J., Baryshnikov, I., Jylhä, P. J., Talaslahti, T., Heikkinen, M. E., & Isometsä, E. T. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05390-8 · Cited by 8
Neuroscience-based nomenclature as a teaching tool, introduction and pilot study
Zemach, S., Levy, D. M., & Zohar, J. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000470 · Cited by 8
“Despite the well established utility of ‘antipsychotics’ in various mental disorders (Brakoulias et al., 2019; Pringsheim et al., 2019; Taylor et al., 2020), 33% of HCPs rarely mention the term ‘atypical antipsychotics’ to patients.”
Parabiaghi, A., Compagnoni, M. M., D’Avanzo, B., Caggiu, G., Galbussera, A. A., Tettamanti, M., Fortino, I., & Barbato, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072073 · Cited by 7
Kato, M., Shiosakai, M., Kuwahara, K., Iba, K., Shimada, Y., Saito, M., Sekine, D., Aoki, K., Shiomi, Y., & Higuchi, T. (2024) · CNS Drugs · doi:10.1007/s40263-024-01124-w · Cited by 5
“Routine monitoring is recommended during treatment with atypical antipsychotics for weight gain, metabolic syndrome, glycolipid metabolism, sedation, extrapyramidal syndrome (EPS), and elevated prolactin levels [17].”
Gallagher, S. P., & Bouchard, L. (2023) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000899 · Cited by 5
Recognition and management of treatment-resistant depression
Ma, C., & Strelow, B. (2024) · JAAPA · doi:10.1097/01.jaa.0000000000000163 · Cited by 3
Smith, A. L. W., Hamilton, S., Murphy, S. E., Cowen, P. J., & Harmer, C. J. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06770-6 · Cited by 2
“However in the treatment of MDD it is noteworthy that vortioxetine, a medication that combines serotonin reuptake inhibition with 5-HT 1A receptor agonism, has beneficial effects on cognition in MDD (Mahableshwarkar et al. 2015; Bennabi et al. 2019) and to a greater extent than treatment with a selective serotonin reu…”
InfluentialCharacterising the severity of treatment resistance in unipolar and bipolar depression
Taylor, R., Strawbridge, R., Young, A. H., Zahn, R., & Cleare, A. J. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1004 · Cited by 3
“5,6 The European Medicines Agency guidelines for the treatment of depression operationalise TRD as a lack of clinically meaningful improvement with adequate treatment trials of at least two different antidepressant agents of the same or different classes, but recognise that validated clinical…”
Self-citationZheng, J., Zhao, Q., Ma, Y., Tian, J., Sun, L., Zhang, Z., & Guo, L. (2023) · PubMed Central · Cited by 2
Thoughtful prescribing for patients with difficult-to-treat depression
Soubolsky, A., Visentin, J. D., & Crawley, A. (2023) · Canadian Family Physician · doi:10.46747/cfp.6911777 · Cited by 2
“Since there is limited evidence to guide medication selection in DTD and variation across guidelines, 11-17 one consensus-based approach is to tailor medication choice to specific symptoms and incorporate patient preference when possible.”
BackgroundBeck, K., & Young, A. H. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241259896 · Cited by 2
“3,4,6 This is in keeping with guidelines published more recently 3 but will likely differ from much of the guidance that will emerge from Europe as opposed to the US, which has fewer fi nancial restrictions on recommendations.”
Self-citationKraft, J., Buspavanich, P., Braun, A., Panagiotaropoulou, G., Schlattmann, P., Buchbauer, H., Heilbron, K., Heilbronner, U., Schulze, T. G., Ripke, S., et al. (2025) · medRxiv · doi:10.1101/2025.01.22.25320940 · Cited by 2
“Lithium, a first-line mood stabilizer in the treatment of bipolar disorder (BIP), is a well-established augmenting agent, and its adjunctive administration after antidepressant non-response and in treatment-resistant depression (TRD). has been recommended by most therapy guidelines (2).”
Choi, W.-S., Woo, Y. S., Bahk, W., Kim, N.-Y., Park, S., Kim, W., Lee, J. G., Yang, C.-M., Sung, H. M., Wang, S., et al. (2025) · 신경정신의학 · doi:10.4306/jknpa.2025.64.3.178 · Cited by 1
When an Antipsychotic Working as an Antidepressant, Do They Have a Therapeutic Window?
Aydın, İ. H., Salifu, A., Settle, K., & El‐Mallakh, R. S. (2025) · Annals of Clinical Psychiatry · doi:10.1177/10401237251344096 · Cited by 2
“16 Also, clinical trials have explored adjunctive doses of cariprazine between 0.1 17 and 4.5 mg. 18,19 In a recent network meta-analysis, the augmen-tative antidepressant effects of dopamine partial agonists, including aripiprazole, brexpiprazole, and cariprazine, were evaluated for…”
InfluentialKetamine for Depression in Serious Illness: Evidence, Safety, and Practical Approaches
Noufi, P. E., Borris, J. B., Chammas, D., McDermott, C. L., Ufere, N. N., Webb, J. A., & Shalev, D. (2026) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2026.04.604 · Cited by 1
The RANZCP 2020 guideline summaries and the need for standardised guideline development
Taylor, R., & Cleare, A. J. (2021) · Bipolar Disorders · doi:10.1111/bdi.13092 · Cited by 1
Self-citationAntiretrovirals and Psychotropics: Drug Interactions and Complications
Smith, C. M., Hicks, P. B., Lindefjeld, J. K., Taylor, B. M., Fisher, D. R., Faragon, J. J., Lam, S. T., Pereira, L. F., & Cozza, K. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-80665-1_17 · Cited by 1
Yang, J., Guo, W., Pang, X., You, C., Zhou, C., Gui, Y., & Ma, D. (2024) · Medicine · doi:10.1097/md.0000000000040253 · Cited by 1
“[14,15] As we know that rTMS uses the principle of electromagnetic induction, in which the magnetic field generated by AC electricity produces induced current, which acts on the cerebral cortex, resulting in the depolarization of neurons in the nervous system.”
Kennedy, K. P., Heldt, J. P., & Oslin, D. W. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002025 · Cited by 3
Hung, Y.-C., Chen, H., Kuo, P., Lu, M., Huang, M., Chen, C.-H., Wang, S. Z., Mao, W., Wu, C.-S., & Wu, T. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s311429 · Cited by 3
“To monitor continuality of medication therapy for patients with chronic diseases, a medication review(10) on clinical outcomes is needed to ensure that patients can access the appropriate medications(11) and treatment guidelines.(12) Our previous study(13) developed a new, multidimensional, clinometric instrument, the…”
Prescription réfléchie pour les patients souffrant d’une dépression difficile à traiter
Soubolsky, A., Visentin, J. D., & Crawley, A. (2023) · Canadian Family Physician · doi:10.46747/cfp.6911e221 · Cited by 1
“Cet article, fondé sur les données probantes et les lignes directrices existantes 8,11-17 , présente l’approche mise de l’avant pour la prise en charge de la dépression difficile à traiter (DDT) et l’application des recommandations pratiques à un cas donné.”
BackgroundTreating schizophrenia: Should we emphasise ‘first do no harm’?
English, T., & Castle, D. J. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211025696
Musa, E., Bohra, M. H., & Shapiro, C. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822963-7.00133-x
Buspavanich, P., & Ricken, R. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_8
Cigognini, M. A. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-10052023-120550
Loosening the Shackles of Depression
McShane, R. H. (2023) · New England Journal of Medicine · doi:10.1056/nejme2309758
Neglect of Adverse Effects in Treatment Guidelines for Depression
Kavirajan, H. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230553
Распопова, Н. И. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202412404169
Management of Major Depressive Disorder: Basic Principles
Arnone, D., Tirumalaraju, V., & Selvaraj, S. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.019
Síndrome de Cotard, Catatonia y Depresión en Adulto Mayor
Pachacama, Y. M. G., Meneses, C. A., Lema, C. G. V., & Gómez, J. L. Q. (2024) · Más Vita · doi:10.47606/acven/mv0230
Römer, N., Gaebler, A. J., Neuner, I., Haen, E., Hiemke, C., Schoretsanitis, G., & Paulzen, M. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2486998 · Cited by 1
“Augmentation strategies, i.e. combining antidepressants with second-generation antipsychotics, are a first-line recommendation [1,2] given by various guidelines [3].”
Predicting suicide attempts in early-onset major depressive disorder: A nomogram-based approach
Lyu, N., Wang, H., Huang, J., Shang, L., Fu, B., Cong, A., Liu, D., Zhang, X., Yang, W., Zhang, L., et al. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.10.050
Świeczkowski, D., Kwaśny, A., & Cubała, W. J. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116878
Kriner, P., Severus, E., Korbmacher, J. M., Mußmann, L., & Seemüller, F. (2024) · Figshare · doi:10.6084/m9.figshare.26656234
von Stackelberg, P., Goedhart, R., Huberts, L. C. E., Lokkerbol, J., & Birbil, Ş. İ. (2025) · Quality and Reliability Engineering International · doi:10.1002/qre.70139 · Cited by 1
“Treatment depends on the severity of symptoms, but is often based on a combination of medication, such as selective serotonin reuptake inhibitors (SSRIs), and psychological approaches (e.g., cognitive behavioral therapy) [ 22, 27–29 ].”
Infante‐Ventura, D., Rodriguez-Díaz, B., García-Bello, M. A., Valcárcel‐Nazco, C., Estupiñán‐Romero, F., Acosta, F. J., de León, B. G., Hurtado, I., & del Pino‐Sedeño, T. (2026) · Depression and Anxiety · doi:10.1155/da/6076326
“…notable presence of anti-psychotics and antiepileptics in treatment regimens may indicate a subset of patients with more complex management needs, requiring broader pharmacological strategies — although the use of anti-epileptics in this context is less well-supported by existing evidence [27, 28].”
Pharmacological augmentation for people with treatment-resistant depression
Strawbridge, R., Nikolova, V. L., Browning, M. D., Rucker, J., Cowen, P. J., Cousins, D. A., Young, A. H., & Cleare, A. J. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10673
Self-citationKwaśny, A., Wilkowska, A., Pastuszak, M., Pastuszak, K., & Cubała, W. J. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00867-1
“Various augmentation strategies have been utilized to improve patient outcomes; however, lithium and atypical antipsychotics appear to be among the most consistently recommended options [2].”
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890427118.bm02
Galbiati, F., Wronski, M., Bitar, T., Bikas, A., Lamont, H., Hiranandani, S., Holman, K., Eddy, K. T., Asanza, E., Smith, S., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag291
Metadata
- Authors
- Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J.
- Affiliations
- King's College London (GB)
- The Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, London, United Kingdom
- Oxford Health NHS Foundation Trust (GB)
- University of Geneva (CH)
- Corresponding author
- Marwood, Lindsey
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-05-13
- Volume
- 23
- Issue
- 9
- Pages
- 587-625
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7710919
- OpenAlex
- W3024119889
- Cited by
- 76
- References
- 341
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 16 · 2023: 17 · 2022: 9 · 2021: 15 · 2020: 3
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute for Health Research
- South London and Maudsley NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- drug augmentation, treatment-resistant depression, major depressive disorder, guideline quality, lithium, atypical antipsychotics, polypharmacy, evidence-based care, guideline recommendations
- MeSH terms
- Major Depressive Disorder, Drug Synergism, Drug Therapy, Combination, Humans, Drug Prescriptions, Antipsychotic Agents, Practice Guidelines as Topic, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
